Origenis, A new approach to small molecule drug discovery

April 29, 2019


A multipart AI-based, drug discovery platform, optimizing compounds for specificity, efficacy, physiochemical properties, and broad patentability (i.e., novelty), in a parallel process is faster, cheaper and better than serial-step traditional drug discovery .

Germany-based Origenis’ mission from day one was to improve and accelerate drug discovery processes to create lead molecules in areas of interest using a unique combination of proprietary in-silico tools for designing compounds (MolMind®) coupled with immediate synthesis and testing of the designed compounds (MOREsystem®). A major advantage of these combined technologies is that they are not limited to a number—even a very large number—of compounds that are contained in in-silico libraries, but use a combination of starting materials and chemical reactions. Use of genetic algorithms, machine learning, and other AI tools allow searching through this chemical space to identify compounds that have activity against a target and can be readily synthesised linking in-silico tools to the lab in a unique way.

MolMind® and MOREsystem® support the design, synthesis and screening A NEW APPROACH TO SMALL MOLECULE DRUG DISCOVERY Origenis SOLUTION PROVIDERS IN EUROPE – 2019 DRUG DISCOVERY & DEVELOPMENT TECH OUTLOOK TOP 10 14 TECH OUTLOOK APRIL – 2019 of compounds in the Origenis labs with interactive AI feedback loops that can alter and enhance the next cycles of design.




origenis gmbh


Am Klopferspitz 19a
82152 Martinsried
Germany

 

Tel: +49.89.7801676.0

Fax: +49.89.7801676.777

email: info(at)origenis.de

Contact Us